Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;14(1):1.
doi: 10.1007/s11306-017-1297-5. Epub 2017 Nov 17.

Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer's disease

Josef Marksteiner  1 , Imrich Blasko  2 , Georg Kemmler  2 , Therese Koal  3 , Christian Humpel  4   5
Affiliations

Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer's disease

Josef Marksteiner et al. Metabolomics. 2018.

Abstract

Introduction: There is still a clear need for a widely available, inexpensive and reliable method to diagnose Alzheimer's disease (AD) and monitor disease progression. Liquid chromatography-mass spectrometry (LC-MS) is a powerful analytic technique with a very high sensitivity and specificity.

Objectives: The aim of the present study is to measure concentrations of 20 bile acids using the novel Kit from Biocrates Life Sciences based on LC-MS technique.

Methods: Twenty bile acid metabolites were quantitatively measured in plasma of 30 cognitively healthy subjects, 20 patients with mild cognitive impairment (MCI) and 30 patients suffering from AD.

Results: Levels of lithocholic acid were significantly enhanced in plasma of AD patients (50 ± 6 nM, p = 0.004) compared to healthy controls (32 ± 3 nM). Lithocholic acid plasma levels of MCI patients (41 ± 4 nM) were not significantly different from healthy subjects or AD patients. Levels of glycochenodeoxycholic acid, glycodeoxycholic acid and glycolithocholic acid were significantly higher in AD patients compared to MCI patients (p < 0.05). All other cholic acid metabolites were not significantly different between healthy subjects, MCI patients and AD patients. ROC analysis shows an overall accuracy of about 66%. Discriminant analysis was used to classify patients and we found that 15/23 were correctly diagnosed. We further showed that LCA levels increased by about 3.2 fold when healthy subjects converted to AD patients within a 8-9 year follow up period. Pathway analysis linked these changes to a putative toxic cholesterol pathway.

Conclusion: In conclusion, 4 bile acids may be useful to diagnose AD in plasma samples despite limitations in diagnostic accuracy.

Keywords: Alzheimer; Bile acid; Biomarkers; Diagnosis; Lithocholic acid; Plasma.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standardsThe authors declare that they have no conflict of interest. TK is employed by Biocrates.The study was approved by the Ethics Committee of the Medical University of Innsbruck and was performed in accordance with the Helsinki Declaration. All subjects gave written informed consent. Data and material are available on request.

Figures

Fig. 1
Fig. 1
Box-and Whisker Plot showing percent change of LCA, GCCA, GDCA and GLCA plasma levels in 8 converters to AD. Eight healthy control patients were included. Blood samples were recollected after 8–9 years (age 77 ± 3 years, 3 male)
Fig. 2
Fig. 2
Pathway analysis showing the putative role of the bile acid metabolites in the cholesterol-pathway. Abbreviations see Table 2
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. The American Journal of Geriatric Psychiatry. 2008;16(5):343–354. doi: 10.1097/01.JGP.0000310778.20870.ae. - DOI - PubMed
    1. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastroinestinal cancers. Mutation Research. 2005;89(1):47–65. doi: 10.1016/j.mrrev.2004.08.001. - DOI - PubMed
    1. Blennow K. CSF biomarkers for Alzheimer’s disease: Use in early diagnosis and evaluation of drug treatment. Expert Review of Molecular Diagnostics. 2005;5:661–672. doi: 10.1586/14737159.5.5.661. - DOI - PubMed
    1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology. 2010;6:131–144. doi: 10.1038/nrneurol.2010.4. - DOI - PubMed
    1. Chiang JY. Bile acid regulation of gene expression: Roles of nuclear hromone receptors. Endocrine Reviews. 2002;23(4):443–463. doi: 10.1210/er.2000-0035. - DOI - PubMed